ArtiSential® for Rectal Cancer Surgery

Seoul National University Hospital93 enrolled

Overview

This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group, based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and resection margin status did not differ between the groups. ArtiSential® reduced operative time without impairing surgical quality or oncologic outcomes.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rectal Cancer

Interventions

ArtiSential®DEVICE

Articulated laparoscopic device made by Livsmed Co, South Korea.

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * mid-to-low rectal caner (witing 10cm of the anal verge) * laparoscopic surgery Exclusion Criteria: * combined surgery * recurrent rectal cancer surgery

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Operation time

To determine whether the use of articulated device can shorten total operative time

Time frame: 0 week

Secondary Outcomes

Long-term Survival

2 year recurrence free survival and 2 year overall survival

Time frame: 2 year

Anastomotic leakage (postop outcome)

anastomotic leakage within one month

Time frame: 4 weeks

TME quality (Operative outcome)

Quality of total mesorectal excision to compare quality of surgery

Time frame: 0 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.